Bausch Health Companies Inc. (BHC) 2026 Q1 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Greetings, and welcome to the Bausch Health's first-quarter 2026 earnings conference call. (Operator Instructions) As a reminder, this conference is being recorded. (Operator Instructions)

    各位好,歡迎參加 Bausch Health 2026 年第一季財報電話會議。(接線員指示) 提醒各位,本次會議將被錄音。(接線員指示)

  • It's now my pleasure to turn the call over to Garen Sarafian, Vice President, Investor Relations. Garen, please go ahead.

    現在我很榮幸將電話會議交給投資人關係副總裁 Garen Sarafian。Garen,請開始。

  • Garen Sarafian - Vice President, Investor Relations

    Garen Sarafian - Vice President, Investor Relations

  • Good afternoon, and welcome to Bausch Health's first-quarter 2026 earnings conference call. My name is Garen Sarafian, Vice President of Investor Relations. Participating in today's call are Thomas Appio, Chief Executive Officer; JJ Charhon, Chief Financial Officer; and Jonathan Sadeh, Chief Medical Officer and Head of Research and Development.

    各位下午好,歡迎參加 Bausch Health 2026 年第一季財報電話會議。我叫 Garen Sarafian,擔任投資人關係副總裁。今天與會者包括執行長 Thomas Appio;財務長 JJ Charhon;以及醫務長兼研發主管 Jonathan Sadeh。

  • Before we begin, I would like to remind you that today's presentation contains forward-looking information. Please take a moment to review the forward-looking statements disclaimer at the beginning of the slides accompanying this presentation, as it contains important information. Actual results may differ materially from those expressed or implied in these forward-looking statements, and you should not place undue reliance on them.

    在開始之前,我想提醒各位,今天的簡報包含前瞻性資訊。請花一點時間閱讀本簡報投影片開頭的前瞻性聲明免責聲明,其中包含重要資訊。實際結果可能與這些前瞻性聲明所明示或暗示者有重大差異,請勿過度依賴。

  • Please also refer to our SEC filings and our filings with the Canadian Securities Administrators for a discussion of certain risk factors that could cause actual results to differ materially from expectations.

    也請參閱我們向 SEC 提交的文件,以及向加拿大證券管理機構提交的文件,其中討論了若干可能導致實際結果與預期有重大差異的風險因素。

  • We use non-GAAP financial measures to help investors better understand our operating performance. These non-GAAP measures may not be comparable to similarly titled measures used by other companies and should be considered in addition to, and not as a substitute for, measures calculated in accordance with GAAP. Reconciliations toward non-GAAP measures are included in the appendix of the slides accompanying this presentation, which are also available on Bausch Health's Investor Relations website.

    我們使用非 GAAP 財務衡量指標,以協助投資人更好地理解我們的營運表現。這些非 GAAP 指標可能無法與其他公司使用的同名指標相互比較,且應作為依 GAAP 計算之指標的補充,而非替代。非 GAAP 指標的調節表載於本簡報投影片的附錄中;投影片亦可於 Bausch Health 投資人關係網站取得。

  • Finally, the financial guidance in this presentation is effective as of today only. We do not undertake any obligation to update guidance. Our discussion today, Wednesday, April 29, will focus on Bausch Health, excluding Bausch + Lomb. However, we will briefly comment on Bausch + Lomb's results announced this morning. We will refer to year-over-year comparisons with the same period last year unless otherwise noted.

    最後,本簡報中的財務指引僅以今日為準。我們不承擔更新指引的任何義務。我們今天(4 月 29 日,星期三)的討論將聚焦於 Bausch Health,不包含 Bausch + Lomb。不過,我們會簡要評論今早公布的 Bausch + Lomb 業績。除非另有說明,我們提及的年對年比較均以去年同期為基準。

  • With that, I will turn the call over to our CEO, Tom Appio. Tom?

    接下來,我把電話交給我們的執行長 Tom Appio。Tom?

  • Thomas Appio - Chief Executive Officer, Director

    Thomas Appio - Chief Executive Officer, Director

  • Thank you, Garen. Thank you to everyone joining us today. We began 2026 with another strong performance. Our first-quarter results extend our track record to 12 consecutive quarters of year-over-year growth in both revenue and adjusted EBITDA for Bausch Health, excluding Bausch + Lomb, reflecting strategic execution and disciplined accountability across our global organization.

    謝謝你,Garen。也感謝今天加入我們的各位。我們以另一個強勁表現開啟 2026 年。我們第一季的結果延續了我們的紀錄:在不含 Bausch + Lomb 的情況下,Bausch Health 的營收與調整後 EBITDA 連續 12 個季度年對年成長,反映我們在全球組織中落實策略執行與嚴謹的責任管理。

  • Our priorities remain. We are focused on execution within our core business, R&D innovation, business development, and optimizing our capital structure. We delivered a strong start to the year in cash flow, supported by solid operating performance. That cash generation supports continued progress on capital structure priorities, enables investments in our businesses, and preserves capital allocation flexibility.

    我們的優先事項不變。我們專注於核心業務的執行、研發創新、業務發展,以及最佳化資本結構。在穩健的營運表現支持下,我們在現金流方面為今年帶來強勁開局。這些現金創造支持我們持續推進資本結構的優先事項,使我們能投資於各項業務,並保有資本配置的彈性。

  • It is also important to consider the composition of reported results this quarter. Core operating performance continues to demonstrate steady growth and is tracking well with expectations. Overall, this was a solid start to the year.

    同時,也必須考量本季已報告結果的組成。核心營運表現持續展現穩健成長,且與預期相當一致。整體而言,這是今年一個扎實的開局。

  • Let me take a moment to share a few highlights from the quarter before handing it over to JJ for a closer look at the financials.

    在把電話交給 JJ 更深入說明財務之前,我先花點時間分享本季幾項重點。

  • Bausch Health, excluding Bausch + Lomb, increased revenue by 14% on a reported basis when compared to the first quarter of 2025. Results were led by Salix and Solta. Within Salix, revenue growth was driven by Xifaxan, which continues to perform well in both IBS-D and OHE. We also benefited from residual volume in certain channels that we exited starting last quarter.

    不含 Bausch + Lomb 的 Bausch Health,與 2025 年第一季相比,按報告基礎營收成長 14%。業績主要由 Salix 與 Solta 帶動。在 Salix 方面,營收成長由 Xifaxan 驅動,其在 IBS-D 與 OHE 兩個適應症上持續表現良好。我們也受惠於自上季開始退出的部分通路所留下的殘餘銷量。

  • Underlying prescription trends remain healthy. Solta continued its double-digit growth trajectory. Demand for systems and consumables remain robust in core markets. Adjusted EBITDA for Bausch Health, excluding Bausch + Lomb, increased by 17% on a reported basis, largely attributable to Salix and Solta performance. Salix benefited from improved margin dynamics following payer channel optimization. And Solta earnings growth was particularly notable given we had a one-time acquisition-related cost.

    處方趨勢的基本面仍然健康。Solta 延續其雙位數成長軌跡。在核心市場中,系統設備與耗材的需求依然強勁。不含 Bausch + Lomb 的 Bausch Health 調整後 EBITDA 按報告基礎成長 17%,主要歸因於 Salix 與 Solta 的表現。Salix 在完成付款方通路最佳化後,受惠於毛利率動能改善。而 Solta 的獲利成長尤其值得注意,因為我們曾有一次性與併購相關的成本。

  • Cash flow generation in the first quarter was healthy and progressing well towards guidance expectation. This includes the remaining settlement of our US opt-out litigation, which have now all concluded, as well as reducing our net debt by over $100 million. Taken together, core operational performance was solid.

    第一季的現金流產生情況健康,並正朝指引預期穩步推進。其中包括我們美國 opt-out 訴訟的剩餘和解款項(目前已全部結案),以及將淨負債降低超過 1 億美元。綜合而言,核心營運表現穩健。

  • Turning briefly to R&D and business development. Through our acquisition of DURECT last year, we are advancing our Larsucosterol Phase 3 program for alcohol-associated hepatitis, where there remains a significant unmet need. We believe Larsucosterol has the potential to be a platform asset with applicability in multiple indications. In recent months, we have made meaningful progress narrowing our broader list of potential indications to those with the strongest scientific and clinical rationale.

    接著簡要談研發與業務發展。透過我們去年對 DURECT 的收購,我們正推進 Larsucosterol 用於酒精相關性肝炎的第三期臨床計畫;該領域仍存在顯著未被滿足的醫療需求。我們相信 Larsucosterol 具有成為平台型資產的潛力,可應用於多個適應症。近幾個月來,我們在縮小更廣泛的潛在適應症清單方面取得實質進展,聚焦於具備最強科學與臨床理據者。

  • Beyond Larsucosterol, we continue to assess multiple business development opportunities that leverage our proven commercial execution and strengthen our R&D pipeline.

    除 Larsucosterol 之外,我們也持續評估多項業務發展機會,以發揮我們經驗證的商業化執行能力並強化研發產品線。

  • Our capital allocation strategy remains consistent and disciplined. We prioritize strengthening the balance sheet through ongoing delevering while we invest in our commercial engine and evaluate business development prospects.

    我們的資本配置策略維持一致且嚴謹。我們在投資商業引擎並評估業務發展前景的同時,優先透過持續去槓桿化來強化資產負債表。

  • Within that framework, we evaluate opportunities selectively across our portfolio, emphasizing assets aligned with our strategic model and our outstanding commercial capabilities. Overall, we are very pleased with our start to the year and the momentum we are carrying forward.

    在此架構下,我們會在整體產品組合中有選擇地評估機會,著重於符合我們策略模式且能發揮我們卓越商業能力的資產。整體而言,我們對今年的開局以及延續至後續的動能感到非常滿意。

  • With that, I will turn the call over to JJ to walk through the detailed financial results. JJ?

    接下來,我把電話交給 JJ,請他帶各位檢視更詳細的財務結果。JJ?

  • Jean-Jacques Charhon - Executive Vice President, Chief Financial Officer

    Jean-Jacques Charhon - Executive Vice President, Chief Financial Officer

  • Thank you, Tom. Let’s review first our non-GAAP financial results for the first quarter, which you will find starting on page 9.

    謝謝你,Tom。讓我們先回顧第一季的非 GAAP 財務結果,相關內容從第 9 頁開始。

  • Revenue was $2.524 billion, up 12% on a reported basis and 7% on an organic basis compared to the same period a year ago. Adjusted gross margin was 70.9%, 100 basis points higher year over year. Adjusted operating expenses were $1.023 billion, an increase of $29 million compared to the same period last year. Please note that this excludes, among other adjustments, the $1.4 billion goodwill impairment charge following the RED-C clinical trial outcome.

    營收為 25.24 億美元,按報告基礎年對年成長 12%,按有機基礎年對年成長 7%。調整後毛利率為 70.9%,年對年提高 100 個基點。調整後營運費用為 10.23 億美元,較去年同期增加 2,900 萬美元。請注意,這不包含(以及其他調整項目)RED-C 臨床試驗結果公布後所認列的 14 億美元商譽減損費用。

  • Adjusted EBITDA was $837 million, an increase of $176 million or a 27% increase year over year. Finally, adjusted operating cash flow was $374 million.

    調整後 EBITDA 為 8.37 億美元,較去年同期增加 1.76 億美元,年增 27%。最後,調整後營運現金流為 3.74 億美元。

  • Moving now to the performance of Bausch Health, excluding Bausch + Lomb, for the first quarter starting on page 11. As Tom indicated earlier, 2026 started on a very strong note. We delivered in Q1 the 12th consecutive quarter of year-over-year revenue and adjusted EBITDA growth, demonstrating once again the consistency of our operational execution.

    現在轉到第 11 頁,回顧 Bausch Health(不含 Bausch + Lomb)第一季的表現。如 Tom 先前所指出,2026 年開局非常強勁。我們在第一季達成連續第 12 個季度的營收與調整後 EBITDA 年增,再次展現我們營運執行的一貫性。

  • The highlights for the quarter were as follows. Revenue was $1.28 billion, up 14% on a reported basis and 9% on an organic basis when compared to the first quarter of 2025. Adjusted EBITDA was $673 million, up 17% year over year, demonstrating our continued commitment to driving profitable growth and leveraging our supply chain and SG&A infrastructure. Finally, adjusted operating cash flow was $319 million, nearly $200 million higher than in the first quarter of 2025, thanks to stronger business performance as well as the difference in timing of our interest payments.

    本季重點如下。營收為 12.8 億美元,較 2025 年第一季按申報基礎年增 14%,按有機基礎年增 9%。調整後 EBITDA 為 6.73 億美元,年增 17%,展現我們持續致力於推動獲利性成長,並發揮供應鏈與銷售、一般及行政(SG&A)基礎設施的槓桿效益。最後,調整後營運現金流為 3.19 億美元,較 2025 年第一季高出近 2 億美元,主要受惠於更強勁的業務表現,以及利息支付時點差異。

  • Moving now to our first-quarter performance by segment, starting with Salix on page 12. Salix had another outstanding quarter. Revenues were $639 million, an increase of $97 million or 18% on a reported basis as compared to the same period last year. Salix strong performance in the first quarter was largely driven by higher-than-expected Xifaxan revenue, which grew 21% year over year.

    接著按事業部門回顧第一季表現,先從第 12 頁的 Salix 開始。Salix 再度交出亮眼的一季。營收為 6.39 億美元,較去年同期按申報基礎增加 9,700 萬美元或 18%。Salix 第一季的強勁表現主要由高於預期的 Xifaxan 營收所帶動,該產品營收年增 21%。

  • This was primarily attributable to continued volume growth in the channel we currently serve, net pricing, and to a lesser extent, the residual volume we are still seeing throughout Medicaid at the state level. Old scripts in the commercial and Medicare channels grew 6% and new-to-brand script growth was 3%.

    這主要歸因於我們目前服務通路的持續量增、淨價格因素,以及在較小程度上,我們在各州層級的 Medicaid 仍觀察到的殘餘用量。商業與 Medicare 通路的既有處方量(old scripts)成長 6%,新用戶處方量(new-to-brand scripts)成長 3%。

  • Now moving to the International segments. Revenues for the quarter were $285 million, which was up 9% on a reported basis and was broadly flat on an organic basis compared to the first quarter of last year. Performance by region was mixed. On an organic basis, EMEA was up 3%, LatAm was flat, while Canada contracted 7% due to its non-promoted portfolio.

    接著看國際事業部。本季營收為 2.85 億美元,按申報基礎年增 9%,與去年第一季相比按有機基礎大致持平。各區域表現不一。按有機基礎計算,EMEA 成長 3%,拉丁美洲(LatAm)持平,而加拿大因其非推廣產品組合而下滑 7%。

  • More specifically, here are the highlights of each geography. EMEA achieved its 13th consecutive quarter of organic revenue growth, which is remarkable. In LatAm, there was solid growth in core commercial products such as Bedoyecta. Conversely, the softness of received orders associated with secured government tenders continues to be a headwind.

    更具體而言,各地區重點如下。EMEA 達成連續第 13 個季度的有機營收成長,表現相當出色。在拉丁美洲,Bedoyecta 等核心商業產品呈現穩健成長。相對地,與已確保的政府標案相關之接單疲弱仍持續構成逆風。

  • In Canada, the performance of our promoted portfolio grew 18%, which was more than offset by the drop in volume in our branded generic portfolio. As a reminder, starting in the second half of 2024 and all the way through the first quarter of 2025, we benefited from higher-than-usual Wellbutrin volumes due to generic supply shortages.

    在加拿大,我們推廣產品組合的表現成長 18%,但被品牌學名藥產品組合的出貨量下滑所抵銷。提醒一下,自 2024 年下半年起至 2025 年第一季,我們因學名藥供應短缺而受惠於高於常態的 Wellbutrin 出貨量。

  • Now moving to page 14 for a review of our Solta Medical segment. Revenues were $171 million, an increase year over year of 51% on a reported basis and 19% on an organic basis. Separately, segment profit grew 42% on a reported basis.

    接著請看第 14 頁,回顧 Solta Medical 事業部。營收為 1.71 億美元,按申報基礎年增 51%,按有機基礎年增 19%。另外,事業部利益(segment profit)按申報基礎成長 42%。

  • Solta’s revenue performance was driven by a 193% year-over-year revenue growth in China. This remarkable performance was partially attributed to higher pricing associated with the integration of our full service distributor, Shibo, we acquired in December 2025, and to our impressive volume growth in the quarter, which stood at 52%. China has now reclaimed the number one position as the largest geography of Solta. South Korea, our second-largest revenue contributor, grew 17% in the first quarter.

    Solta 的營收表現主要由中國市場營收年增 193% 所帶動。這項亮眼表現部分歸因於我們於 2025 年 12 月收購並整合全方位服務經銷商 Shibo 所帶來的較高定價,以及本季達 52% 的強勁量增。中國現已重新成為 Solta 最大的市場。南韓作為我們第二大營收貢獻地,第一季成長 17%。

  • Outside of the APAC region, the US, EMEA, and Canada also showed positive momentum, delivering high-single to low-double-digit reported revenue growth in the quarter.

    在亞太(APAC)以外,美國、EMEA 與加拿大亦展現正向動能,本季申報營收成長介於高個位數至低雙位數。

  • Finally, please note, [Solta] segment profit in Q1 was impacted by the residual impact of the higher inventory cost associated with the Shibo acquisition.

    最後請注意,Solta 事業部第一季的事業部利益受到與 Shibo 收購相關之較高庫存成本的殘餘影響。

  • Turning now to our Diversified segments, which you will find on page 15. Revenues were $185 million, a decrease of 10% on a reported basis compared to the same period a year ago. The Diversified segment’s performance is largely driven by our neuroscience business. The year-over-year revenue contraction this quarter was due to lower volume, partially offset by favorable pricing.

    接著看第 15 頁的多元化事業部。營收為 1.85 億美元,較去年同期按申報基礎下滑 10%。多元化事業部的表現主要由我們的神經科學業務所驅動。本季營收年減主要因出貨量較低,部分被有利的定價所抵銷。

  • Finally, Bausch + Lomb revenues were $1,244 million, up 9% on a reported basis and 6% on an organic basis compared to the same period last year.

    最後,Bausch + Lomb 營收為 12.44 億美元,較去年同期按申報基礎成長 9%,按有機基礎成長 6%。

  • Now turning our focus to our balance sheet. Our net debt, excluding Bausch + Lomb, decreased by approximately $150 million (sic – see slide 5, "$115 million") in the first quarter. This is after an approximately $160 million outflow due to various legacy litigations, which included the last set of payments of our US opt-out settlements.

    現在將焦點轉向資產負債表。第一季我們的淨負債(不含 Bausch + Lomb)約減少 1.5 億美元(原文如此——見第 5 張投影片「1.15 億美元」)。此數字已反映約 1.6 億美元的現金流出,係因多項歷史訴訟所致,其中包含我們美國 opt-out 和解的最後一筆付款。

  • Before wrapping up with our financial priorities, let’s review our full-year guidance, which you will find on page 19. We are reaffirming our full-year 2026 guidance for Bausch Health, excluding Bausch + Lomb, which remains as follows.

    在以財務優先事項作結之前,我們先回顧第 19 頁的全年指引。我們重申 Bausch Health(不含 Bausch + Lomb)2026 年全年指引如下。

  • Revenue is expected to be between $5.25 billion and $5.4 billion. The midpoint of that range would translate into a 3% increase year over year. Adjusted EBITDA is expected to be between $2.875 billion and $2.95 billion, representing a 4% increase year over year at the midpoint. The 2026 guidance for adjusted EBITDA now includes the anticipated impact of the new tariffs on pharma products expected to be effective on September 29, 2026.

    營收預期介於 52.5 億至 54 億美元。該區間中點相當於年增 3%。調整後 EBITDA 預期介於 28.75 億至 29.5 億美元,按中點計算相當於年增 4%。2026 年調整後 EBITDA 指引現已納入預期將於 2026 年 9 月 29 日生效之藥品新關稅的影響。

  • Finally, we expect adjusted operating cash flow to be between $1.2 billion and $1.275 billion. The midpoint of that range would translate to a 4% increase year over year. Please also note that the guidance for 2026 is at current FX rates.

    最後,我們預期調整後營運現金流介於 12 億至 12.75 億美元。該區間中點相當於年增 4%。另請注意,2026 年指引係以目前外匯(FX)匯率為基礎。

  • Before I turn it over to Tom for his wrap-up, let me review our financial priorities, which remain broadly unchanged.

    在我把時間交給 Tom 進行總結之前,我先回顧我們的財務優先事項,整體而言仍大致不變。

  • First, increasing the value of Bausch Health. Our management team remains committed to driving profitable growth through innovation, excellence in operational execution, effective resource investments, and selective business development projects.

    第一,提升 Bausch Health 的價值。我們的管理團隊仍致力於透過創新、卓越的營運執行、有效的資源投入,以及具選擇性的業務發展專案,推動獲利性成長。

  • Second, evaluating all options for unlocking value for all stakeholders, including maximizing the value of the Bausch Health and Bausch + Lomb assets. On the B+L front, we believe in Bausch + Lomb management team and their Vision ’27 plan. We fully expect the financial markets to reward B+L’s progress in the future. This will likely guide, among other consideration, the timing of our equity stake monetization.

    第二,評估所有可為所有利害關係人釋放價值的選項,包括最大化 Bausch Health 與 Bausch + Lomb 資產的價值。在 B+L 方面,我們相信 Bausch + Lomb 管理團隊及其 Vision ’27 計畫。我們完全預期金融市場未來將回饋並肯定 B+L 的進展。這很可能將在其他考量因素之中,指引我們股權持份變現的時點。

  • And third, optimizing our capital structure. While our current debt maturity profile allows us to take a more opportunistic approach to capital allocation decision, we will continue to look at all options to improve our liquidity and financial flexibility.

    第三,優化我們的資本結構。雖然我們目前的債務到期結構使我們能以更具機會性的方式來進行資本配置決策,但我們將持續檢視所有選項,以改善流動性與財務彈性。

  • In summary, we had a great first quarter and remain confident in our financial outlook given the strength of our current operational momentum.

    總結而言,我們第一季表現非常出色,且鑑於目前營運動能的強勁,我們對財務展望仍具信心。

  • I will now hand it back to Tom.

    我現在把時間交還給 Tom。

  • Thomas Appio - Chief Executive Officer, Director

    Thomas Appio - Chief Executive Officer, Director

  • Thank you, JJ. Looking ahead, we see continued progress building our company for growth in 2026 and beyond. Throughout our markets, we are gaining share, seeing favorable prescription trends, expanding partnerships, advancing new product launches, and extending the reach of our existing products to new geographies. This progress reflects strong execution within our portfolio, the integration of new businesses and disciplined investments that strengthen our competitive position.

    謝謝你,JJ。展望未來,我們看到在打造公司以於 2026 年及更長遠實現成長方面持續取得進展。在我們所處的各個市場,我們正在提升市占、看到有利的處方趨勢、擴大合作夥伴關係、推進新產品上市,並將既有產品的觸及範圍延伸至新的地理區域。這些進展反映了我們在產品組合上的強勁執行力、新業務的整合,以及強化競爭地位的紀律性投資。

  • As we have noted on prior calls, certain dynamics relating to our exit from Medicaid and 340B may impact our growth as reflected in our Salix and Diversified segments in the back half of the year. Even so, we are excited about initiatives underway across the portfolio to ensure we plant the seeds for future growth.

    如同我們在先前電話會議中提到的,與我們退出 Medicaid 與 340B 相關的某些動態,可能會在今年下半年對成長造成影響,並反映在我們的 Salix 與 Diversified 事業部門。即便如此,我們仍對整個產品組合中正在推進的各項計畫感到振奮,以確保我們為未來成長播下種子。

  • A few examples from different segments illustrate the breadth of that progress.

    以下來自不同事業部門的幾個例子,說明這些進展的廣度。

  • Within US (technical difficulty) deployment, we are focusing our resources on high growth opportunities that drive demand and operational efficiency.

    在美國(技術問題)部署方面,我們正將資源聚焦於能推動需求與營運效率的高成長機會。

  • At Salix, this approach continues to translate into strong performance for Xifaxan, supported by high levels of physician engagement, improved patient access, and a channel mix that reinforce both stability and scale. We are investing thoughtfully, prioritizing returns, and optimizing growth that can be realized from a highly resilient, well-established franchise.

    在 Salix,這種做法持續轉化為 Xifaxan 的強勁表現,並由高度的醫師互動、更佳的病患可近性,以及能同時強化穩定性與規模的通路組合所支撐。我們審慎投資、以報酬為優先,並優化可從一個高度韌性、成熟且根基深厚的產品系列中實現的成長。

  • Turning to Solta China. We are pleased with our integration of the Shibo distribution business, which is progressing as planned. By deepening our vertical integration within this core market, this acquisition secures a critical segment of our value chain. It provides unfiltered visibility into end consumer behavior, enabling more precise demand forecasting and strengthening our long-term competitive advantage.

    接著談 Solta 中國。我們對 Shibo 經銷業務的整合感到滿意,且正按計畫推進。透過在此核心市場深化垂直整合,這項收購鞏固了我們價值鏈中的關鍵環節。它讓我們能不經過濾地掌握終端消費者行為,從而更精準地進行需求預測,並強化我們的長期競爭優勢。

  • In EMEA, 2026 is expected to be an active year for new product launches. Products launched in 2025 and those launching throughout this year are expected to contribute meaningfully to growth in 2026 and beyond. We are currently have more than 30 products launching in 10 countries within EMEA, spanning gastroenterology, dermatology, joint health, neurology, and hospital-based therapies. We are also targeting geographic expansion of existing portfolio products, including Poland and Serbia, Montenegro.

    在 EMEA,預期 2026 年將是新產品上市相當活躍的一年。於 2025 年上市的產品,以及今年全年陸續上市的產品,預期將在 2026 年及其後對成長做出實質貢獻。目前我們在 EMEA 的 10 個國家有超過 30 項產品上市,涵蓋腸胃科、皮膚科、關節健康、神經科與院內治療。我們也鎖定既有產品組合的地理擴張,包括波蘭以及塞爾維亞、蒙特內哥羅。

  • In Latin America, we continue to extend our cardiometabolic franchise. In addition to the three products launched in Mexico during the back half of last year, two additional therapies are expected to launch in the second quarter.

    在拉丁美洲,我們持續延伸心臟代謝產品系列。除了去年下半年在墨西哥上市的三項產品外,預期第二季還將再上市兩項療法。

  • Within Solta, we launched Clear + Brilliant in Canada, expanding access to advanced aesthetics technologies in new markets. Within dermatology, our collaboration with the FDA has successfully streamlined patient access for Salix. Patients can now begin their journey with this specialty medication sooner, as pre-prescription blood tests are no longer a requirement for starting on-site sampling.

    在 Solta,我們在加拿大推出 Clear + Brilliant,將先進醫美技術的可近性擴展至新市場。在皮膚科方面,我們與 FDA 的合作已成功簡化 Salix 的病患可近性流程。由於處方前的血液檢測不再是開始現場試用取樣的必要條件,病患現在可以更早開始使用這項專科用藥的療程旅程。

  • More recently, in mid-April, we also launched Biafine in the US. First developed in France, this heritage formulation is gentle for sensitive skin, is scientifically proven to fortify the skin barrier, and is now available without the need of a prescription.

    更近期地,在 4 月中旬,我們也在美國推出 Biafine。此經典配方最初於法國研發,對敏感肌溫和,並經科學證實可強化皮膚屏障,且現已可在無需處方的情況下取得。

  • While these investments vary in scale, each is a strategic building block in our global portfolio. They reflect our commitment to investing with purpose, ensuring we have the right mix of products to drive consistent operational excellence across the entire organization.

    雖然這些投資在規模上各不相同,但每一項都是我們全球產品組合中的策略性基石。它們反映了我們以明確目的進行投資的承諾,確保我們具備適當的產品組合,以推動整個組織持續一致的卓越營運。

  • Beyond product innovation, we continue scaling our core capabilities. Given the frequent questions, I want to dive deeper into our AI roadmap and how it’s delivering our growth.

    除了產品創新之外,我們也持續擴大核心能力。鑑於外界經常提問,我想更深入說明我們的 AI 路線圖,以及它如何帶動我們的成長。

  • We were early in recognizing the potential of AI to drive commercial performance, and that conviction has paid off. Our AI-enabled customer insights engine, first developed for Xifaxan, has been instrumental in the continued growth of the brand within both OHE and IBS-D indications. These insights ensure our field teams are engaging the right customers at the right frequency with the right message.

    我們很早就看見 AI 推動商業表現的潛力,而這份信念已獲得回報。我們的 AI 驅動客戶洞察引擎最初為 Xifaxan 開發,對該品牌在 OHE 與 IBS-D 兩項適應症的持續成長發揮了關鍵作用。這些洞察確保我們的前線團隊以正確的頻率、用正確的訊息,與正確的客戶互動。

  • Since the 2023 launch of the customer insights engine, we have seen a 20% surge in sales productivity. More importantly, this efficiency has enabled nearly 700,000 Xifaxan new patient starts, directly advancing our mission to deliver better health outcomes for those living with OHE and IBS-D.

    自 2023 年推出客戶洞察引擎以來,我們看到銷售生產力提升了 20%。更重要的是,這項效率提升促成近 700,000 名 Xifaxan 新病患開始用藥,直接推進我們為 OHE 與 IBS-D 病患帶來更佳健康結果的使命。

  • These core capabilities are evolving in a suite of digital tools that streamline the HCP experience while significantly increasing the precision and impact of our promotional efforts. Building on that foundation, we have expanded AI-driven insights in additional US pharmaceutical brands at various stages of field force deployment.

    這些核心能力正演進為一套數位工具,既能簡化醫療專業人員(HCP)的體驗,也能顯著提升我們推廣活動的精準度與影響力。在此基礎上,我們已將 AI 驅動洞察擴展至其他美國藥品品牌,並處於不同的前線部署階段。

  • For Relistor, we launched an AI-enabled program in the second half of 2025. While still early, our preliminary data suggests as much as a 20%-plus lift in new prescriptions with certain high-priority HCP cohorts. And with the most recent launch of the Customer Insights Engine for neurosciences late in the first quarter, all US pharmaceutical business now leverage AI and advanced analytics, driving meaningful increase in field productivity and effectiveness.

    針對 Relistor,我們在 2025 年下半年推出 AI 賦能計畫。雖然仍在早期階段,我們的初步數據顯示,對某些高優先級 HCP 族群,新處方量可能提升超過 20%。而隨著第一季末神經科領域最新推出客戶洞察引擎,目前所有美國藥品業務皆運用 AI 與先進分析,推動前線生產力與效能的顯著提升。

  • On the other end of the spectrum, AI is also playing an expanded role in accelerating both the efficiency and effectiveness of our R&D organization, spanning operations, clinical development, medical affairs, pharmacovigilance, and project management. Three examples illustrate the tangible impact.

    在另一端,AI 也在加速提升我們研發組織的效率與效能方面扮演更擴大的角色,涵蓋營運、臨床開發、醫學事務、藥物安全監測與專案管理。以下三個例子說明其具體影響。

  • In clinical operations, we leverage AI-enabled site selection and patient recruitment models to evaluate site expertise and patient population, expanding our qualified investigator network. Not only did the number of eligible sites increase by a substantial margin in less time, but we believe this has led to a significant increase in high-quality investigator sites expected to reduce recruitment timelines and study costs relative to traditional meta-methods.

    在臨床營運方面,我們運用 AI 賦能的試驗中心選址與病患招募模型,評估中心專業能力與病患族群,擴大合格研究者網絡。合格中心數量不僅在更短時間內大幅增加,我們也相信這已帶來高品質研究者中心的顯著提升,預期可相較於傳統統合方法縮短招募時程並降低研究成本。

  • Pharmacovigilance is a second area of impact, where AI-assisted workflows are eliminating months of manual effort and improving the speed and consistency of our safety monitoring.

    藥物安全監測是第二個產生影響的領域,AI 輔助的工作流程正在消除數月的人工作業,並提升我們安全監測的速度與一致性。

  • Finally, in indication selection, we applied AI-driven analysis to our full asset portfolio, integrating internal data with public domain sources to identify potential new indications, as well as model probability of success and sharpen prioritization.

    最後,在適應症選擇方面,我們對完整資產組合應用 AI 驅動分析,將內部數據與公共領域來源整合,以識別潛在的新適應症,同時建模成功機率並強化優先順序排序。

  • While we are in the early stages of our AI transformation, our initial targeted applications have already delivered measurable impact. These early wins give us the confidence to invest in building a sustainable competitive advantage in how we develop and market life-changing medicines.

    雖然我們的 AI 轉型仍處於早期階段,但我們最初的重點應用已經帶來可衡量的成效。這些早期成果讓我們更有信心投入資源,建立我們在研發與行銷改變生命的藥物方面的可持續競爭優勢。

  • Lastly, I want to highlight our continued focus on business development.

    最後,我想強調我們對業務發展的持續聚焦。

  • Our approach is disciplined and consistent with the financial priorities I outlined earlier. We are actively screening opportunities based on therapeutic fit with a focus on areas where we have established expertise, including GI, hepatology, neurosciences, dermatology, and aesthetics, and where we believe we can create the most value.

    我們的方法嚴謹且一貫,並與我先前概述的財務優先事項一致。我們正積極篩選機會,依據與治療領域契合度來評估,重點放在我們已建立專業能力的領域,包括腸胃(GI)、肝病學、神經科學、皮膚科與醫美,並聚焦於我們相信能創造最大價值之處。

  • We are prioritizing assets that are late-stage or commercial-ready, where our existing outstanding commercial capabilities allow for efficient execution from development to commercialization across the markets. This focus helps ensure that any potential investment is aligned with how we operate the business today.

    我們優先考量後期或已具備商業化條件的資產,因為我們既有且卓越的商業能力,能讓我們在各市場從開發到商業化進行高效率的執行。這項聚焦有助於確保任何潛在投資都與我們目前的營運方式一致。

  • We continue to screen opportunities through the lens of our capital allocation strategy. By first ensuring an efficient capital structure, we can then focus on disciplined investments and business development that deliver sustainable long-term value creation.

    我們持續以資本配置策略的視角來篩選機會。在先確保資本結構有效率之後,我們便能專注於嚴謹的投資與業務發展,以帶來可持續的長期價值創造。

  • In closing, our solid first-quarter performance is a testament to our global team’s relentless commitment to operational excellence. Our performance in the first quarter gives the confidence to reaffirm our full-year guidance. As we strengthen our balance sheet and execute with discipline, we remain steadfast in our mission to drive long-term value for shareholders.

    總結來說,我們第一季的穩健表現,證明了我們全球團隊對卓越營運不懈投入。第一季的表現讓我們有信心重申全年財測指引。在我們強化資產負債表並以紀律執行之際,我們仍堅定致力於為股東創造長期價值。

  • With that, can we open the line for Q&A? Operator?

    那麼,我們可以開放進入問答環節嗎?接線員?

  • Operator

    Operator

  • (Operator Instructions) Les Sulewski, Truist.

    (接線員指示) Les Sulewski,Truist。

  • Unidentified Participant

    Unidentified Participant

  • Hey, this is Jeevan on for Les. Thanks for taking our questions. What are your expectations for the Xifaxan inventory, the stocking in 4Q due to IRA? Do you have any color on how you expect wholesalers to act ahead of the pricing step down in 2027?

    嗨,我是代替 Les 的 Jeevan。謝謝你們回答我們的問題。你們對 Xifaxan 的庫存有何預期,尤其是因 IRA 而在第四季的備貨?對於 2027 年價格下調之前,批發商可能會如何行動,你們能否提供一些看法?

  • Thomas Appio - Chief Executive Officer, Director

    Thomas Appio - Chief Executive Officer, Director

  • Yeah, I think, JJ, you can take that.

    好的,我想 JJ,你可以回答這題。

  • Jean-Jacques Charhon - Executive Vice President, Chief Financial Officer

    Jean-Jacques Charhon - Executive Vice President, Chief Financial Officer

  • Yeah. In terms of volume, there’s really not that much destocking. As we indicated, during our full-quarter call, is that we’re expecting a gross to net accrual adjustment as a result of that higher discount rate, that will be effective January 1, 2027. So that will be an entry we will take.

    好的。就銷量而言,其實並沒有太多去庫存(destocking)。如同我們在上一季完整季度的電話會議中所提到的,我們預期會因較高的折扣率而進行「毛額到淨額」(gross-to-net)的應計調整,該折扣率將於 2027 年 1 月 1 日生效。因此,我們會認列一筆分錄。

  • In terms of volume, we’re not anticipating any change versus the current volume we’re seeing right now.

    就銷量而言,我們不預期會相較於目前看到的水準出現任何變化。

  • Operator

    Operator

  • Douglas Miehm, RBC Capital Markets.

    Douglas Miehm,RBC Capital Markets。

  • Douglas Miehm - Analyst

    Douglas Miehm - Analyst

  • Very strong numbers that came out of Solta, especially out of China. Of course, part of that is a function of the Shibo acquisition and seeing a full quarter of that. But even so, you did have 22% organic growth, I believe.

    Solta 公布的數字非常強勁,尤其是中國市場。當然,其中一部分是因為收購 Shibo,並且本季反映了完整一季的貢獻。但即便如此,我記得你們的有機成長仍有 22%。

  • I’m just wondering, that seems in contrast to a couple other companies that we’ve heard recently, including B+L this morning, who says that’s probably their weakest market. So just wondering why you’re having so much success over there and if it’s sustainable?

    我只是想了解,這似乎與我們近期聽到的其他幾家公司形成對比,包括今天早上 B+L 表示那可能是他們最疲弱的市場。所以想請教你們為何在那邊能有這麼大的成功,以及這是否具有可持續性?

  • Thomas Appio - Chief Executive Officer, Director

    Thomas Appio - Chief Executive Officer, Director

  • Thanks, Doug. Thanks for the question. I think the first thing, as you mentioned, the acquisition of Shibo was that was a part of what we wanted to build there to be able to get closer to the providers and the customers and the consumer.

    謝謝你,Doug。謝謝你的提問。我想第一點,如你所提到的,收購 Shibo 是我們希望在當地建立能力的一部分,讓我們能更貼近醫療服務提供者、客戶以及消費者。

  • What I would say is, we have an outstanding team in China. We have a team that is executing to precision. The integration is going extremely well. What we’re seeing right now is there’s high demand. As I mentioned during the last conference call, I was in China at the end of December. We had an event where we met the key customers in China. And the product is viewed as the gold standard.

    我想說的是,我們在中國有一支非常出色的團隊。團隊執行精準到位。整合進展非常順利。我們目前看到的是需求很高。如同我在上次法說會提到的,我在 12 月底去了中國。我們舉辦了一場活動,與中國的關鍵客戶會面。而該產品被視為黃金標準。

  • So now having this integration, having direct access to the providers, the consumers, and also to the field force, and then developing the processes and enhancing the processes to have a better sales execution is what’s driving it. You know, the Thermage business in China, the customer, in terms of their ability to pay, it’s a very -- it’s a business and a customer base that is sort of a little bit insulated from the economics that are going on in the country or even globally.

    因此,透過這次整合、直接接觸醫療服務提供者與消費者,以及第一線銷售團隊,再加上建立流程並強化流程以提升銷售執行力,這些都是推動成長的因素。你知道,在中國的 Thermage 業務,客戶就其支付能力而言,是一個在某種程度上相對不太受國內甚至全球經濟情勢影響的業務與客群。

  • So we still see strong demand for the product. As you know, it’s a durable business, both with capital and consumables. So the more capital we can put in with this integration of Shibo and then driving the use of those machines going forward with our consumable base. So we see that the growth can continue, and we’re expecting a very good year in 2026. And as I said, it all begins with having an outstanding team on the ground in China.

    因此我們仍看到該產品需求強勁。如你所知,這是一個具耐久性的業務,同時涵蓋資本設備與耗材。所以,透過 Shibo 的整合,我們能投入更多資本設備,並在未來推動這些設備的使用量,進而帶動我們的耗材基礎。因此我們認為成長可以延續,並預期 2026 年會是非常好的一年。如我所說,一切都始於我們在中國當地擁有一支卓越的團隊。

  • Douglas Miehm - Analyst

    Douglas Miehm - Analyst

  • Okay, great. Just with respect to business development, as a follow-up question, given the success that you’re seeing at Solta, but also the importance of your GI franchise, capital commitment, opportunities, those sorts of things, which of those two businesses, are you just going to be simply opportunistic? Like, where would you expect to see some investment go?

    好的,很棒。關於業務發展,作為追問,考量你們在 Solta 看到的成功,以及你們腸胃(GI)事業的重要性、資本承諾、機會等因素,在這兩個業務之間,你們會只是採取機會主義的做法嗎?你們預期投資會流向哪裡?

  • Thomas Appio - Chief Executive Officer, Director

    Thomas Appio - Chief Executive Officer, Director

  • Doug, another great question. You know, when I look at it, in terms from a business development standpoint, and I look at our US Pharmaceutical business, along with our International Pharmaceutical business, again, it starts with people.

    Doug,又是一個很好的問題。你知道,當我從業務發展的角度來看,並看我們的美國製藥業務以及國際製藥業務時,歸根結底仍是從人才開始。

  • We have an outstanding global commercial team. As we’re looking at business development opportunities, what I see for Bausch Health, our greatest asset is our people and being able to execute globally. So as we look at various opportunities throughout the therapeutic areas that we have expertise in, I see opportunities to be able to bring in some products that we can grow and we can develop.

    我們擁有一支卓越的全球商業團隊。在我們評估業務發展機會時,我認為對 Bausch Health 而言,我們最大的資產是我們的人才,以及在全球範圍內的執行能力。因此,當我們在各個我們具備專業能力的治療領域中尋找不同機會時,我看到的是:我們有機會引進一些產品,並將其做大、並進一步開發。

  • So as I said in my prepared remarks, looking at, assets that are, commercially already on the market or coming to market and at the same time, having a pipeline, we have an outstanding R&D team as well to be able to develop some of those pipeline assets.

    所以如我在事先準備的發言中所說,我們會看那些已在市場上商業化、或即將上市的資產;同時也會看管線。

  • So overall, I’m not specifically looking at areas in the therapeutic classes that we compete. But we have, if you look at Xifaxan, then you look at the OHE indication, that’s really a specialty area. So we have expertise to be able to sell, and market specialty drugs or, extending off of that into the rare space.

    總體而言,我並不是特別只鎖定我們所競爭的某些治療類別。但如果你看 Xifaxan,再看 OHE 適應症,那其實是一個專科領域。因此我們具備銷售與行銷專科藥物的專業能力,或以此為延伸進入罕見疾病領域。

  • At the same time also, on the Solta side, we’re also looking at other opportunities as well, in terms of there’s a few assets that we could look at to bring in. So overall, really robust discussions happening here to get more products into the hands of our outstanding commercial teams.

    同時,在 Solta 這一端,我們也在尋找其他機會;就引進而言,確實有幾項資產是我們可以評估納入的。因此整體來看,這裡正在進行非常強而有力的討論,以便把更多產品交到我們優秀的商業團隊手中。

  • Operator

    Operator

  • (Operator Instructions) Umer Raffat, Evercore ISI.

    (接線員指示) Umer Raffat,Evercore ISI。

  • Umer Raffat - Equity Analyst

    Umer Raffat - Equity Analyst

  • I have two here, if I may. First, your planning around separation, debt refi, et cetera, how does that change, considering your current scenario is January 2028. How does that change if the DC Circuit Court reverses some of the prior findings of courts? And how does that change the level of urgency and planning? Do you have a contingency plan in place if that were to happen on Xifaxan?

    如果可以的話,我有兩個問題。第一,關於你們對分拆、債務再融資等的規劃,考量你們目前的情境是 2028 年 1 月,這些規劃會如何改變?如果 DC 巡迴上訴法院推翻先前法院的一些認定,會如何影響?緊迫性與規劃程度會如何改變?如果 Xifaxan 發生那種情況,你們是否已有應變計畫?

  • Number two, JJ, you mentioned looking at tuck-in opportunities for assets that are either already on the market or coming to market with a pipeline. I guess my question is, do you guys have the flexibility and room to be able to raise equity to finance some of those? Because this is a strategy that’s been used very successfully by a lot of SMID biotechs. But what I didn’t know is do you have the visibility on being able to raise cash from the markets to finance those R&D and the trials in case you were to find a good asset, let’s say a Chinese asset or the like?

    第二,JJ,你提到在尋找一些「tuck-in」機會,針對已在市場上或即將上市、且帶有產品線(pipeline)的資產。我想問的是,你們是否有彈性與空間可以透過增資(發行股權)來為其中一些交易融資?因為這是一個許多中小型生技公司(SMID biotechs)非常成功使用過的策略。但我不確定的是,你們是否能見度足夠、能從資本市場籌到現金來支應那些研發與試驗成本;假設你們找到一個好資產,例如中國的資產或類似的?

  • Thomas Appio - Chief Executive Officer, Director

    Thomas Appio - Chief Executive Officer, Director

  • Okay. Umer, I’ll take the first part of your question and hand it off to JJ for the second part. Thanks for calling in and the question.

    好的。Umer,我先回答你問題的第一部分,第二部分我會交給 JJ。謝謝你來電與提問。

  • You know, the way I’m looking at it right now, we know we will have a generic entrant, 1/1/2028. But right now, today, Teva remains the first filer -- has first filer status. If we look at it, as you know, recently, the one thing that has changed is that Teva has gained final approval by the FDA.

    你知道,我目前的看法是,我們知道在 2028/1/1 會有學名藥進入市場。但就目前、今天而言,Teva 仍然是首家申請者——仍具首家申請者(first filer)身分。如你所知,最近唯一改變的是 Teva 已取得 FDA 的最終核准。

  • So as we look at it, there’s two appeal cases that are fully briefed, and we are waiting on a decision. You know, clearly, as I said, we remain a generic entrant of 1/1/2028. As I look at it, and we look at what our contingency planning is, of course, we always looking at contingencies and what we would do, but we continue to remain confident in our IP and planning for 1/1/2028.

    因此我們來看,目前有兩個上訴案件已完成所有書狀提交,我們正在等待裁決。你知道,正如我所說,我們仍以 2028/1/1 有學名藥進入為前提。就我來看,以及我們的應變規劃而言,當然我們一直都在思考各種備案與可能採取的作法,但我們仍對自身的智慧財產權有信心,並以 2028/1/1 來規劃。

  • JJ?

    JJ?

  • Jean-Jacques Charhon - Executive Vice President, Chief Financial Officer

    Jean-Jacques Charhon - Executive Vice President, Chief Financial Officer

  • Yeah. Hi, Umer. Let me take a step back first and probably reiterate the equation we’re dealing with. As you know, our capital structure optimization really relies on three variables.

    是的。嗨,Umer。我先退一步,可能重申一下我們正在面對的等式。如你所知,我們的資本結構最佳化主要仰賴三個變數。

  • The first variable is the free cash flow we’ll be generating between now and the end of 2027, assuming obviously we retain exclusivity until the first of January 2028. The second variable is the AP depot, Xifaxan LOE. And then the third variable is the average selling price we hope to get by monetizing our equity stake in BLCO in completing the separation, if that’s the path we’re going to be taking.

    第一個變數是從現在到 2027 年底我們將產生的自由現金流,當然前提是假設我們能維持獨占到 2028 年 1 月 1 日。第二個變數是 AP depot、Xifaxan 的專利到期(LOE)。第三個變數是:若我們走分拆這條路,在完成分拆並將我們在 BLCO 的股權部位變現時,我們希望取得的平均售價。

  • In case we lose exclusivity before January 1, 2028, what it does, as is that basically it curtails the free cash flow generation between now and the end of 2027. So that would translate into, in the absence of any other levers that we would put in place, the need to monetize some of our assets earlier than originally planned.

    如果我們在 2028 年 1 月 1 日之前就失去獨占,基本上會壓縮我們從現在到 2027 年底的自由現金流產生。因此,在沒有啟動其他槓桿的情況下,這會轉化為:我們需要比原先規劃更早將部分資產變現。

  • But from a operational standpoint, I think Tom covered it. Obviously it’s an event we’ve been preparing for. You know, we’re trying to mitigate it as much as possible through looking at potential BD opportunities, but it’s not something that would be a dramatic change of plans.

    但從營運角度來看,我想 Tom 已經說明了。顯然這是我們一直在準備的事件。你知道,我們正透過評估潛在的商務開發(BD)機會,盡可能降低其影響,但這不會導致計畫出現劇烈改變。

  • There are opportunities to increase our level of financial flexibility. I think, I mentioned that in my prepared remarks, the ability to potentially do some other refinancing of our debt structure so that the maturities between now and the end of 2028 could be pushed back. That would be one option. The other options would be to do some sort of capital reallocation within our portfolio.

    我們也有機會提升財務彈性。我想我在事先準備的發言中提過:我們可能進一步對債務結構做一些再融資,將現在到 2028 年底之間的到期日往後延。這會是一個選項。其他選項則是,在我們的投資組合內進行某種形式的資本重新配置。

  • Equity is not something that is high on our priority list at this stage, given where the share price is. So I certainly wouldn’t consider that. It’s a possibility, it’s probably not a probability at this stage.

    在這個階段,考量股價水準,發行股權並不是我們優先事項清單上的高順位。所以我當然不會把它當作主要考量。它是可能性,但在此階段大概不是高機率事件。

  • Operator

    Operator

  • Mike Nedelcovych, TD Cowen.

    Mike Nedelcovych,TD Cowen。

  • Michael Nedelcovych - Equity Analyst

    Michael Nedelcovych - Equity Analyst

  • I have three actually, if that’s all right. My first is on Larsucosterol. What are the key changes that have been made to the Phase 3 trial to avoid the failure that was seen in Phase 2B? Is it just a larger, better powered trial, or have there been other changes made to trial design or inclusion criteria? That’s my first question.

    其實我有三個問題,如果可以的話。第一個是關於 Larsucosterol。第三期試驗做了哪些關鍵改動,以避免第二期 B(Phase 2B)所見到的失敗?只是做成更大、統計力更足的試驗而已,還是試驗設計或納入標準也有其他改動?這是我的第一個問題。

  • My second question is just a simple one. I’m just curious where the internal review for Amiselimod stands? It’s been underway for some time and just wondering what factors are still being considered.

    第二個問題很簡單。我只是好奇 Amiselimod 的內部審查目前進展到哪裡?已經進行一段時間了,想了解目前仍在考量哪些因素。

  • My third question relates to your tariff exposure. I think since you last quantified your tariff exposure, there’s been news from the White House. So I’m wondering if you might be able to characterize your current tariff exposure with a little bit more detail.

    第三個問題與你們的關稅曝險有關。我想自從你們上次量化關稅曝險以來,白宮又有新的消息。因此我想請你們更詳細地說明目前的關稅曝險狀況。

  • Thomas Appio - Chief Executive Officer, Director

    Thomas Appio - Chief Executive Officer, Director

  • Yeah, Michael, thanks for the three questions. I’ll take the last one, and then I’ll hand it off to Jonathan for your first two.

    好的,Michael,謝謝你這三個問題。我先回答最後一個,然後把前兩個交給 Jonathan。

  • As -- generally speaking, we have local production in many of the markets, so -- which naturally helps us there. And then the recently announced tariffs, that probably will have an impact on Xifaxan and Trulance starting in September, or the end of September of 2026.

    一般來說,我們在許多市場都有在地生產,因此——這自然對我們有幫助。而最近宣布的關稅,可能會從 2026 年 9 月或 2026 年 9 月底開始,對 Xifaxan 與 Trulance 產生影響。

  • What I would say is as of today that we noted in our guidance that we reaffirmed, it includes the impact of any existing tariffs or those signed to become effective in 2026. So right now, that’s the way we see it, with, well, what we know today.

    我想說的是,截至今天,我們在已重申的財測指引中已註明:其中包含任何現行關稅,或那些已簽署、將於 2026 年生效的關稅之影響。所以就目前而言,這就是我們的看法——以我們今天所掌握的資訊為準。

  • JJ, you want anything else on tariffs?

    JJ,你還想補充關於關稅的其他內容嗎?

  • Jean-Jacques Charhon - Executive Vice President, Chief Financial Officer

    Jean-Jacques Charhon - Executive Vice President, Chief Financial Officer

  • No, I would just say at the high level, it’s minimal impact in 2026. 2027, we’ll have to wait until what mitigants we put in place to try to minimize even more, assume obviously those tariffs stay in place for the full year of 2027. But at this stage, I think what we have provided earlier, which is that tariff has a minimal impact on our P&L, I think remains the same even with the latest round of tariffs.

    不,我只想說從高層面來看,2026年的影響很小。2027年,我們得等到看看我們會採取哪些緩解措施來進一步把影響降到最低,當然前提是假設這些關稅在2027年全年都維持不變。但在這個階段,我認為我們先前提供的資訊——也就是關稅對我們的損益表(P&L)影響很小——即使在最新一輪關稅之後仍然不變。

  • Thomas Appio - Chief Executive Officer, Director

    Thomas Appio - Chief Executive Officer, Director

  • Jonathan, you want to take the first two parts of that question?

    Jonathan,你要先回答那個問題的前兩個部分嗎?

  • Jonathan Sadeh - Chief Medical Officer and Head of Research and Development

    Jonathan Sadeh - Chief Medical Officer and Head of Research and Development

  • Yes. Okay. So first of all, Larsucosterol, your question is, what have we done to mitigate for what happened to DURECT in their Phase 2B study?

    是的。好的。那麼首先,關於Larsucosterol,你的問題是:我們做了什麼來因應DURECT在其2B期研究中發生的情況?

  • First, it’s important to remember what really happened there. Remember, it was a global study, although about 80% of the patients were in the US, about 20% were ex-US. And when we reviewed the data, it seemed like the 20% of patients who were randomized outside of the US were somewhat different than the ones in the US.

    首先,重要的是要記得那裡實際發生了什麼。請記得,那是一項全球性研究,雖然約80%的病患在美國,約20%在美國以外。當我們審視資料時,看起來在美國以外被隨機分派的那20%病患,與美國的病患有些不同。

  • The main issues there were that those patients seemed to be randomized later on. So this -- the earlier you’re randomized after presentation to the hospital with alcohol-associated hepatitis, the sooner you’re randomized, the more likely you were to respond, which of course makes sense.

    主要問題在於,那些病患似乎是在較晚的時間點才被隨機分派。也就是說——在因酒精相關性肝炎就醫後,越早被隨機分派,越可能有反應,這當然合乎邏輯。

  • Ex-US, there were a few sites where they really took a very long time to randomize these patients. Mainly, we believe based on different treatment algorithms in some of these countries, they took a long time to rule out any other issues, any problems they had. And so they randomized them sometimes weeks after presentation. So the ability of the drug to actually be impactful was much lower.

    在美國以外,有少數研究中心確實花了很長時間才將這些病患進行隨機分派。我們主要認為,基於其中一些國家的治療流程不同,他們花了很久時間去排除其他任何狀況、任何可能的問題。因此他們有時是在就醫後數週才進行隨機分派。所以藥物實際能發揮影響的能力就低得多。

  • It also seemed to be like a slightly different patient population. They’re heavier drinkers than they were in the US. So all of those together -- all those issues together, when we look at the US patient population, it was a much more homogeneous patient population, all randomized early on after presentation to the drug. And we consistently saw a very strong effect of over 50% reduction in mortality in this patient population.

    看起來也像是略有不同的病患族群。他們的飲酒量比美國的病患更高。因此綜合所有這些——把所有這些問題放在一起看,當我們看美國的病患族群時,那是一個更同質的族群,且都是在就醫後較早期就被隨機分派接受藥物。而我們在這個病患族群中一致地看到非常強的效果,死亡率降低超過50%。

  • So we strongly believe that that is true and that is a real finding, was highly statistically significant in the US population. And what we’ve done to make sure that we don’t see those same issues in the Phase 3 trial was first to focus on the US population. We want to make sure that we’re taking a homogeneous patient population, so we decided to run the trial in the US only.

    因此我們堅信那是真的、而且是一個真實的發現,在美國族群中具有高度統計顯著性。而我們為了確保在3期試驗中不會再看到同樣的問題,首先就是聚焦在美國族群。我們希望確保納入的是同質的病患族群,因此我們決定只在美國進行這項試驗。

  • Second is we made sure that patients are randomized early on. They cannot be randomized for the drug unless they are unless they’re randomized within nine days of presentation, which is what we saw in the Phase 2B trial. Those patients seem to have a strong response. So that was the second important adjustment.

    第二,我們確保病患會在早期就被隨機分派。除非病患在就醫後九天內完成隨機分派,否則不能被隨機分派接受該藥物,這也是我們在2B期試驗中看到的情況。那些病患似乎有很強的反應。所以這是第二個重要調整。

  • And the third, as you’re alluding to, we did power the study, highly to 90% alpha. Made sure that we have a very large number of patients randomized active and placebo, and we believe that the probability of success here, based on all of these, is quite high.

    第三,如你所提到的,我們確實把研究的統計把握度(power)設計得很高,達到90%的alpha。並確保有非常大量的病患被隨機分派至治療組與安慰劑組;我們相信基於以上各點,成功的機率相當高。

  • The study is now in start mode. We’re opening up sites and are very optimistic about the probability of success here. That’s the Larsucosterol question.

    這項研究現在已進入啟動階段。我們正在開設研究中心,並對此成功機率非常樂觀。以上就是關於Larsucosterol的問題。

  • The second was about the review of Amiselimod, and maybe I should take a broader view here and tell you what we’ve been doing as looking at our portfolio overall and looking at not just Amiselimod. We have -- we got the data on UC a while back and have been reviewing it. The data we thought was very good. The indication is a one of interest for us and fits well with our strategy.

    第二個問題是關於Amiselimod的審視;也許我應該從更宏觀的角度來回答,告訴你我們如何檢視整體產品組合,而不只是Amiselimod。我們——我們在一段時間前就拿到了UC的資料並一直在審視。我們認為資料非常好。這個適應症是我們感興趣的方向之一,也很符合我們的策略。

  • But what we have been doing over the past few months is looking at all possible indications with all possible drugs that we have in our hands right now. So Larsucosterol is one. We have -- we’ve said before that that is a platform drug that can be used for multiple indications. So we have been looking at possible indications to progress with that. We’ve been looking at Rifaximin, which is, I think a really effective drug, and we have multiple formulation of that, and we’ve been looking at possibilities for new indications there as well as with Amiselimod.

    但我們在過去幾個月所做的,是檢視我們目前手上所有藥物在所有可能適應症上的可能性。Larsucosterol是其中之一。我們之前也說過,那是一個平台型藥物,可用於多種適應症。因此我們一直在評估可推進的適應症。我們也在評估Rifaximin,我認為那是一個非常有效的藥物,而且我們有多種劑型;我們也在評估它在新適應症上的可能性,同時也包括Amiselimod。

  • So we’ve put all those indications together, all the possibilities, and we’re right now prioritizing what is the best indication for us to progress forward based on scientific evidence, developability of drugs, regulatory path, and importantly, commercial opportunity. We’re looking at all of those variables for all indications and making decisions with all drugs and all indications and making decisions on which ones we will progress with.

    因此我們把所有這些適應症、所有可能性整合在一起,目前正在依據科學證據、藥物可開發性、法規路徑,以及很重要的商業機會,來排定優先順序,決定對我們而言最適合推進的適應症。我們正在針對所有適應症檢視上述所有變數,並就所有藥物與所有適應症做出決策,決定哪些會繼續推進。

  • Operator

    Operator

  • Thank you. We’ve reached the end of our question-and-answer session. I’ll just turn the floor back over to Tom Appio for any further closing comments.

    謝謝。我們的問答環節到此結束。我把時間交回給Tom Appio,請他做任何進一步的結語。

  • Thomas Appio - Chief Executive Officer, Director

    Thomas Appio - Chief Executive Officer, Director

  • Thank you, operator. Thank you all for joining us today and for your questions.

    謝謝,接線員。也謝謝各位今天的參與以及提問。

  • We had a solid first-quarter performance, and I want to thank the global Bausch Health team for their relentless commitment to operational excellence and delivering of results. We are committed to our mission to drive long-term value for our shareholders.

    我們第一季表現穩健,我要感謝Bausch Health全球團隊對營運卓越與成果交付的不懈承諾。我們致力於我們的使命,為股東創造長期價值。

  • Thank you for your time today and your interest in our company. Have a good evening.

    感謝各位今天撥冗,以及對我們公司的關注。祝各位晚安。

  • Operator

    Operator

  • Thank you. That does conclude today’s teleconference and webcast. You may disconnect your line at this time and have a wonderful day. We thank you for your participation today.

    謝謝。今天的電話會議與網路直播到此結束。您現在可以掛斷電話,祝您有美好的一天。感謝您今天的參與。